- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pacira Pharmaceuticals Inc (PCRX)
Assess today's live Pacira Pharmaceuticals Inc (PCRX) share price, performance and insights using our live NASDAQ: PCRX stock exchange data.
Analyse the historical data and Pacira Pharmaceuticals Inc share price performance charts on this page. Our technical summary section provides analysis on Pacira share price buy/sell indicators using real-time data (or discuss the Pacira (PCRX) stock price today with other investors in the Pacira NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ PCRX share price (ISIN: US6951271005) to enhance your trading decisions with our free investment tools and resources.
What Is the Pacira Pharmaceuticals Inc Share Price Today?
The Pacira share price today is 24.45.
What Is the Stock Symbol for Pacira Pharmaceuticals Inc
The stock symbol (or 'ticker') for Pacira Pharmaceuticals Inc is "PCRX."
What Stock Exchange Does Pacira Pharmaceuticals Inc Trade On?
Pacira Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Pacira Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Pacira Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Pacira Pharmaceuticals Inc share price performance charts on this page. Our technical summary section provides analysis on Pacira share price buy/sell indicators using real-time data (or discuss the Pacira (PCRX) stock price today with other investors in the Pacira NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ PCRX share price (ISIN: US6951271005) to enhance your trading decisions with our free investment tools and resources.
What Is the Pacira Pharmaceuticals Inc Share Price Today?
The Pacira share price today is 24.45.
What Is the Stock Symbol for Pacira Pharmaceuticals Inc
The stock symbol (or 'ticker') for Pacira Pharmaceuticals Inc is "PCRX."
What Stock Exchange Does Pacira Pharmaceuticals Inc Trade On?
Pacira Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Pacira Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Pacira Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
24.45
+0.11(+0.45%)
Closed·
After Hours
24.91+0.46(+1.88%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
23.50
24.59
52 wk Range
11.16
29.61
PCRX Scorecard
Full Analysis
Management has been aggressively buying back shares
PCRX is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
23.5024.59
52 wk Range
11.1629.61
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PCRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
30.40
Upside
+24.34%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Pacira Company Profile
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Pacira Pharmaceuticals Inc SWOT Analysis
Patent Peril | Explore Pacira's battle against generic competition as legal challenges threaten its flagship product Exparel, potentially eroding market share and revenues |
NOPAIN, Big Gain? | Delve into Pacira's NOPAIN initiative and new partnerships, offering hope for growth amid challenges in the non-opioid pain management market |
Outpatient Opportunity | Learn how recent CMS rule changes could boost Pacira's Exparel and iovera adoption in outpatient settings, expanding market reach |
Financial Fortitude | Analysts set price targets ranging from $14 to $37, with Pacira's strong margins and cash flow suggesting resilience despite market headwinds |
Pacira Pharmaceuticals Inc Earnings Call Summary for Q1/2025
- Q1 2025 revenue of $164.9M missed forecasts, causing 4.76% stock drop in aftermarket trading
- EXPAREL sales rose to $136.5M, but ZILRETTA sales declined to $23.3M; non-GAAP gross margin improved to 81%
- 2025 revenue guidance set at $725M-$765M; 'No Pain' program expected to boost market share in H2
- Patent protection for EXPAREL extended to 2039; strategic initiatives include sales force restructuring
- CEO highlighted 'five by 30 path to value creation'; CMO emphasized potential of PCRX-201 for osteoarthritis
Last Updated: 08/05/2025, 22:58
Read Full TranscriptCompare PCRX to Peers and Sector
Metrics to compare | PCRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPCRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.9x | −4.1x | −0.5x | |
PEG Ratio | 0.04 | 0.13 | 0.00 | |
Price/Book | 1.4x | 1.1x | 2.6x | |
Price / LTM Sales | 1.6x | 10.8x | 3.1x | |
Upside (Analyst Target) | 15.0% | 107.0% | 48.3% | |
Fair Value Upside | Unlock | 0.7% | 7.6% | Unlock |
Analyst Ratings
2 Buy
3 Hold
1 Sell
Ratings:
6 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 30.40
(+24.34% Upside)
Earnings
Latest Release
May 08, 2025
EPS / Forecast
0.62 / 0.59
Revenue / Forecast
168.92M / 175.60M
People Also Watch
FAQ
What Is the Pacira (PCRX) Stock Price Today?
The Pacira stock price today is 24.45
What Stock Exchange Does Pacira Trade On?
Pacira is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Pacira?
The stock symbol for Pacira is "PCRX."
What Is the Pacira Market Cap?
As of today, Pacira market cap is 1.13B.
What Is Pacira's Earnings Per Share (TTM)?
The Pacira EPS (TTM) is -2.25.
When Is the Next Pacira Earnings Date?
Pacira will release its next earnings report on 04 Aug 2025.
From a Technical Analysis Perspective, Is PCRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Pacira Stock Split?
Pacira has split 0 times.
How Many Employees Does Pacira Have?
Pacira has 789 employees.
What is the current trading status of Pacira (PCRX)?
As of 13 Jun 2025, Pacira (PCRX) is trading at a price of 24.45, with a previous close of 24.34. The stock has fluctuated within a day range of 23.50 to 24.59, while its 52-week range spans from 11.16 to 29.61.
What Is Pacira (PCRX) Price Target According to Analysts?
The average 12-month price target for Pacira is USD30.4, with a high estimate of USD44 and a low estimate of USD24. 2 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +24.34% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.